3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Follicular
6
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma
3
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Neoplasms
1
Lymphoma, B-Cell
1
Interventions
Rituximab
18
Cyclophosphamide
17
Prednisone
12
Doxorubicin
12
Vincristine
9
Lenalidomide
7
ibrutinib
6
obinutuzumab
5
glofitamab
5
Magnetic Resonance Spectroscopy
5
polatuzumab vedotin
4
fludarabine
4
Prednisolone
4
Oxaliplatin
4
Gemcitabine
4
Etoposide
4
venetoclax
3
pembrolizumab
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Specimen Handling
3
R-CHOP protocol
3
Cyclosporine
3
Biopsy
3
zanubrutinib
2
prednylidene
2
deltacortene
2
acalabrutinib
2
Mycophenolic Acid
2
Ifosfamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
Bendamustine Hydrochloride
×
30 days
×
Clear all
NCT05139017
2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
290 enrolled
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled